Item 1.01 Entry into a Material Definitive Agreement.
On
Pursuant to the terms of the Agreement, WCT will provide services to enroll
approximately one hundred (100) Study subjects.
Unless earlier terminated under the provisions of the Agreement, the Agreement will expire upon WCT's completed performance of the services thereunder (including delivery of all the deliverables) and WCT's receipt of all payments from Neurotrope BioScience that are due under the Agreement. In addition to Neurotrope BioScience's termination right described above, Neurotrope BioScience may terminate the Agreement immediately due to patient safety. Further, under the Agreement, either Neurotrope BioScience or WCT may terminate the Agreement if the other party materially breaches the Agreement and fails to cure such breach. Additionally, either Neurotrope BioScience or WCT may terminate the Agreement upon notice to the other party if the other party is adjudicated insolvent or petitions for relief under any insolvency, re-organization, receivership, liquidation, compromise, or any moratorium statute.
The foregoing description of the Agreement is qualified in its entirety by reference to the Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated in its entirety into this Item 1.01 by reference.
Item 9.01 Financial Statements and Exhibits
The following exhibit is filed herewith:
(d) Exhibits. Exhibit No. Description 10.1* Services Agreement, by and betweenWorldwide Clinical Trials, Inc. andNeurotrope BioScience Inc. , dated as ofJuly 23, 2020 . * Confidential treatment has been requested for certain portions of this exhibit. The unredacted document will be provided supplementally to theSecurities and Exchange Commission upon request
© Edgar Online, source